** Lipella Pharmaceuticals' shares rise 7% to $2.59 premarket
** LIPO says completed dosing of first group of patients in mid-stage study of LP-310, its key experimental drug to treat oral lichen planus
** OLP is a chronic inflammatory disease that affects mucous membranes inside the mouth
** Disease affects about 6-7 million Americans, and has no approved drug besides those used to alleviate symptoms, the co's website says
** As of last close, stock had fallen 70% YTD
(Reporting by Leroy Leo in Bengaluru)
((Leroy.Dsouza@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。